Overview
Problem: 20% to 40% of Dutch patients are non-adherent to their prescribed treatments; they do not take their medications according to the agreed-upon instructions with their (general) practitioner. The consequences are significant. Non-adherence reduces the quality of life and increases the risk of morbidity and mortality. Every year, more than 1600 heart patients die due to non-adherence. Non-adherence results in up to €1.5 billion in additional healthcare costs annually (prolonged treatment, more expensive medications, hospitalizations) and between €9 and €13 billion in economic productivity losses (sick leave, absenteeism, reduced productivity). Improving adherence could yield around €2.4 billion for society (Booz & Co 2012). The consequences of non-adherence are therefore enormous.
Solution: Understanding who, when, and why people are non-adherent will better enable us to support these individuals, increase self-management and self-sufficiency, improve adherence, and enhance positive health. A crucial first step will be to measure adherence on a large scale and investigate how non-adherence relates to people’s behavior.
Project: MLK will create an app that will be used to gather responses to the MARS-5 questionnaire, and these responses will be added to MLK’s data lake. Obseq B.V. will use MLK’s Kilimanjaro platform to analyse the data alongside VioScore™ with the aim to discover insights into the medication adherence of the respondents. With their organizational expertise and knowledge of adherence, Obsess B.V. will be able to support healthcare providers, employers, financial institutions, and governments in measuring, analyzing, reporting, and advising on the causes and consequences of adherence and how to deal with it.
Partner | Obseq B.V. |
Title | MEDA-S |
Date | Coming Soon |